Elutia to Participate in Upcoming Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Elutia (Nasdaq: ELUT), a leader in drug-eluting biomatrix products, has announced its participation in two upcoming investor conferences in New York. Dr. Randy Mills, President and CEO, and Matt Ferguson, CFO, will represent the company at these events:
1. H.C. Wainwright 26th Annual Global Investment Conference:
- Presentation available on-demand from September 9, 2024, 7:00 a.m. ET
- One-on-one meetings on September 11, 2024
2. Lake Street Capital Markets 8th Annual Best Ideas Growth Conference:
- One-on-one meetings on September 12, 2024
Institutional investors can arrange meetings with Elutia's management through their H.C. Wainwright and Lake Street representatives.
Details
News Market Reaction – ELUT
The recorded move for ELUT in the trading session of this news was -1.48%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SILVER SPRING, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, and Matt Ferguson, Chief Financial Officer, will participate in the following upcoming investor conferences in New York:
H.C. Wainwright 26th Annual Global Investment Conference
Format: Presentation and 1x1 Meetings
Presentation Date and Time (On-demand beginning): Monday, September 9, 2024, 7:00 a.m. ET
1x1 Meetings: Wednesday, September 11, 2024
Webcast: Click here
Lake Street Capital Markets 8th Annual Best Ideas Growth Conference
Format: 1x1 Meetings
Date: Thursday, September 12, 2024
Institutional investors interested in meeting with management during the conferences may reach out to their respective H.C. Wainwright and Lake Street representatives.
About Elutia
Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com.
Investors:
Matt Steinberg
FINN Partners
matt.steinberg@finnpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.